Overview

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-119 Injection in Chinese Obese Subjects

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-04-29
Target enrollment:
Participant gender:
Summary
The trial is conducted in a single-center, randomized, double-blind, placebocontrolled, dose-increasing design. To evaluate the safety, tolerability, pharmacokinetics(PK) characteristics, efficacy and immunogenicity of PB-119 injection in Chinese obese subjects.
Phase:
PHASE1
Details
Lead Sponsor:
PegBio Co., Ltd.